Resveratrol Supported on Magnesium DiHydroxide (Resv@MDH) Represents an Oral Formulation of Resveratrol With Better Gastric Absorption and Bioavailability Respect to Pure Resveratrol

被引:25
作者
Iannitti, Rossana Giulietta [1 ]
Floridi, Alessandro [2 ]
Lazzarini, Andrea [2 ]
Tantucci, Alice [3 ]
Russo, Roberta [3 ]
Ragonese, Francesco [4 ]
Monarca, Lorenzo [4 ]
Caglioti, Concetta [4 ]
Spogli, Roberto [5 ]
Leonardi, Lucio [1 ]
De Angelis, Massimiliano [3 ]
Palazzetti, Federico [4 ]
Fioretti, Bernard [4 ]
机构
[1] S&R Farmaceutici SpA, Perugia, Italy
[2] CRABioN Res Ctr, Forens Toxicol Lab, Perugia, Italy
[3] Univ Perugia, Dept Med, Perugia, Italy
[4] Univ Perugia, Dept Chem Biol & Biotechnol, Perugia, Italy
[5] Univ Perugia, Spin Off Un, Prolabin & Tefarm, Perugia, Italy
来源
FRONTIERS IN NUTRITION | 2020年 / 7卷
关键词
resveratrol; human health; bioavailability; dissolution rate; whole blood concentration; TRANS-RESVERATROL; PROFILE; SIRT1;
D O I
10.3389/fnut.2020.570047
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Resveratrol attracts great interest because of the plethora of in vitro effects at the micromolar concentration range. Unfortunately, these effects are difficult to establish in vivo, due to the low concentration of resveratrol reached. This discrepancy is due to the molecules low solubility in water that favors the propensity for an intestinal absorption rather than in the gastric compartment. To address these challenges, we developed a Solid Dispersion of Resveratrol Supported by Magnesium Di Hydroxide formulation (Resv@MDH). This formulation displays increased water solubility and better bioavailability relative to pure resveratrol in the rabbit animal model. In our study, we evaluated the pharmacokinetics profile of resveratrol in six healthy human subjects following 180 mg of oral resveratrol administration, derived from Resv@MDH or pure resveratrol. Free resveratrol was evaluated in the whole blood sample by using HPLC - MS/MS. In comparison with pure resveratrol that displays an increase of the maximum plasma concentration, Cmax at about 90 min and 2 mu M, Resv@MDH displays an earlier peak of resveratrol concentration with an increase of Cmax at about 30 min and 6 mu M. The different kinetics suggest a main gastric route for resveratrol absorption from Resv@MDH, where, because of its improved dissolution rate, there seems to be a higher propensity for an acidic environment, as opposed to that with pure resveratrol. This conclusion is also supported by the numerical simulation analysis, which considers the principal steps during the oral route administration. Moreover, there is a 2-fold increase in the amount of free resveratrol with respect to pure resveratrol confirming a better bioavailability observed in the animal model. The characteristic feature of the pharmacokinetic profile of Resv@MDH implies that the beneficial properties of resveratrol in human health should be capitalized on it.
引用
收藏
页数:10
相关论文
共 28 条
  • [1] Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers
    Almeida, Luis
    Vaz-da-Silva, Manuel
    Falcao, Amilcar
    Soares, Eva
    Costa, Raquel
    Loureiro, Ana I.
    Fernandes-Lopes, Carlos
    Rocha, Jose-Francisco
    Nunes, Teresa
    Wright, Lyndon
    Soares-da-Silva, Patricio
    [J]. MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 : S7 - S15
  • [2] Administration of resveratrol: What formulation solutions to bioavailability limitations?
    Amri, A.
    Chaumeil, J. C.
    Sfar, S.
    Charrueau, C.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 158 (02) : 182 - 193
  • [3] Therapeutic potential of resveratrol:: the in vivo evidence
    Baur, Joseph A.
    Sinclair, David A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) : 493 - 506
  • [4] Determination of Quercetin and Resveratrol in Whole Blood-Implications for Bioavailability Studies
    Biasutto, Lucia
    Marotta, Ester
    Garbisa, Spiridione
    Zoratti, Mario
    Paradisi, Cristina
    [J]. MOLECULES, 2010, 15 (09): : 6570 - 6579
  • [5] Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent
    Boocock, David J.
    Faust, Guy E. S.
    Patel, Ketan R.
    Schinas, Anna M.
    Brown, Victoria A.
    Ducharme, Murray P.
    Booth, Tristan D.
    Crowell, James A.
    Perloff, Marjorie
    Gescher, Andreas J.
    Steward, William P.
    Brenner, Dean E.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (06) : 1246 - 1252
  • [6] Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides -: Two novel resveratrol metabolites in human plasma
    Burkon, Alexander
    Somoza, Veronika
    [J]. MOLECULAR NUTRITION & FOOD RESEARCH, 2008, 52 (05) : 549 - 557
  • [7] Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
    Jang, MS
    Cai, EN
    Udeani, GO
    Slowing, KV
    Thomas, CF
    Beecher, CWW
    Fong, HHS
    Farnsworth, NR
    Kinghorn, AD
    Mehta, RG
    Moon, RC
    Pezzuto, JM
    [J]. SCIENCE, 1997, 275 (5297) : 218 - 220
  • [8] Resveratrol transport and metabolism by human intestinal Caco-2 cells
    Kaldas, MI
    Walle, UK
    Walle, T
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (03) : 307 - 312
  • [9] Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease
    Kou, Xianjuan
    Chen, Ning
    [J]. NUTRIENTS, 2017, 9 (09):
  • [10] Resveratrol protects mice from paraquat-induced lung injury: The important role of SIRT1 and NRF2 antioxidant pathways
    Li, Shengqin
    Zlia, Guangju
    Chen, Longwang
    Ding, Yinwei
    Lian, Jie
    Hong, Guangliang
    Lu, Zhongqiu
    [J]. MOLECULAR MEDICINE REPORTS, 2016, 13 (02) : 1833 - 1838